Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 4
2002 1
2003 2
2004 5
2005 7
2006 7
2007 5
2008 7
2009 4
2010 7
2011 2
2012 2
2014 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
North Central Cancer Treatment Group--achievements and perspectives.
Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC; North Central Cancer Treatment Group. Grothey A, et al. Semin Oncol. 2008 Oct;35(5):530-44. doi: 10.1053/j.seminoncol.2008.07.006. Semin Oncol. 2008. PMID: 18929151 Free PMC article. Review.
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE; North Central Cancer Treatment Group. Garrity MM, et al. J Clin Oncol. 2004 May 1;22(9):1572-82. doi: 10.1200/JCO.2004.10.042. J Clin Oncol. 2004. PMID: 15117979
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.
Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B; North Central Cancer Treatment Group. Jatoi A, et al. J Clin Oncol. 2004 Jun 15;22(12):2469-76. doi: 10.1200/JCO.2004.06.024. J Clin Oncol. 2004. PMID: 15197210 Clinical Trial.
Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
Edmonson JH, Suman VJ, Dalton RJ, Bro WC, Gallenberg MM, Long HJ, Levitt R, Hatfield AK, Krook JE, Mailliard JA, Gerstner JB; North Central Cancer Treatment Group. Edmonson JH, et al. Cancer Invest. 2001;19(6):597-602. doi: 10.1081/cnv-100104287. Cancer Invest. 2001. PMID: 11486702 Clinical Trial.
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC; North Central Cancer Treatment Group Study N0177. Brown PD, et al. J Clin Oncol. 2008 Dec 1;26(34):5603-9. doi: 10.1200/JCO.2008.18.0612. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955445 Free PMC article. Clinical Trial.
51 results